by hzhang | Sep 12, 2024 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
by hzhang | Aug 6, 2024 | Press Releases
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...
by hzhang | Mar 6, 2024 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology March 6, 2024: Nature Biotechnology, a transformative journal covering the science and...
by hzhang | Oct 26, 2023 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a...
by hzhang | Oct 23, 2023 | Press Releases
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law...
Recent Comments